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Hyperthyroidism is associated with significant morbidity and 
mortality, especially from cardiovascular complications.[1] It occurs 
due to excessive production or release of thyroid hormone by the 
thyroid gland. The common causes of excessive hormone production 
are Graves’ disease, multinodular goitre and functional adenoma. 
Three modalities are available for treatment of hyperthyroidism. 
Radio-iodine (RAI) ablation is most commonly used where it is 
available.[1-3] The other modalities are antithyroid drugs (ATDs) and 
surgery. RAI treatment was introduced in 1941 and has become a 
preferred modality of treatment of hyperthyroidism because of its low 
cost and low complication rate.[4,5] The perception of optimal RAI use 
differs significantly among physicians.[2] 
Several factors have been considered as influencing the outcome of 
RAI treatment, such as the RAI dose, patient age and sex, the cause of 
hyperthyroidism and the use of ATD drugs.[3,6] There has been much 
debate about the concomitant use of ATDs during RAI treatment.[7,8] 
ATDs are used as adjunctive treatment of hyperthyroidism, especially 
because there is a significant lag period in the hyperthyroid patient 
before RAI’s suppressive effects are manifested, and RAI therapy 
may lead to a transient rise of circulating thyroid hormone as a 
result of radiation thyroiditis. The optimal use and timing of ATD 
treatment during RAI has not been determined. The question arises 
whether ATDs are a necessary or even counterproductive adjunctive 
treatment in RAI therapy. 
The aim of this study was to determine the cure rate in hyperthyroid 
patients with Graves’ disease treated with RAI and to assess the 
influence of associated use of ATD treatment. 
Methods
A retrospective study was undertaken of RAI treatment of patients 
with Graves’ disease at Steve Biko Academic (SBAH) and Kalafong 
hospitals. These tertiary hospitals serve the northern areas of 
Gauteng Province and Mpumalanga Province and are part of the 
training platform of the University of Pretoria. The study population 
comprised all patients treated for Graves’ disease with RAI at the 
Department of Nuclear Medicine of SBAH during the period 2005 - 
2015. Patients were identified from the records of the Department 
of Nuclear Medicine and the data on RAI treatment were retrieved. 
Demographic, clinical and follow-up details were obtained from 
the records from the referral clinics within these two hospitals. 
Biochemical data in files (triiodothyronine (T3), thyroxine (T4) and 
thyroid-stimulating hormone (TSH)) were correlated with laboratory 
data from the National Health Laboratory Services (NHLS). All 
patients underwent an iodine-123 (123I) or technetium-99m (Tc 99m) 
uptake scan which was also used for planning RAI treatment. The 
diagnosis was confirmed by the presence of anti-TSH receptor 
antibodies.
The usual practice at the Department of Nuclear Medicine in 
treating Graves’ disease is to administer varying doses of RAI at the 
discretion of the treating nuclear medicine doctor, depending on 
the size of the thyroid gland and the degree of pretreatment iodine 
uptake. Therapeutic RAI was given as a single oral dose of 131I. Follow-
up of the patients included biochemical thyroid function tests (TFTs), 
repeated at 3, 6, 9 and 12 months. Therapy with carbimazole was at 
the discretion of the clinical or nuclear medicine treating doctor. 
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Background. Radioactive iodine (RAI) is widely used in the treatment of hyperthyroidism. Adjunctive antithyroid drugs (ATDs) are 
commonly prescribed to treat the hyperthyroid state before the RAI has taken effect. However, there is no consensus on the use of or timing 
of adjunctive ATD treatment with RAI. 
Objectives. To determine the influence of the ATD carbimazole on the cure rate of RAI treatment for Graves’ disease.
Methods. A retrospective chart review was conducted in the Department of Nuclear Medicine of the Steve Biko Academic Hospital in 
Pretoria. The cure rate of patients treated with RAI for Graves’ disease was analysed. The effect of adjunctive carbimazole treatment with 
regard to its use and timing with RAI dosing was analysed. The cure rate was determined in patients treated with carbimazole either before 
RAI or before and after RAI administration. Cure rate was defined by the biochemical thyroid function status (thyroxine (T4), thyroid-
stimulating hormone (TSH)) as euthyroid or hypothyroid from 3 months and sustained at 12 months. The need for a second dose of RAI 
was recorded.
Results. RAI treatment was administered to 171 patients with Graves’ disease. The cure rate was higher in patients receiving a higher dose 
of RAI. The overall cure rate increased progressively from 3 months and was 91% at 12 months. The cure rate in 97 patients not receiving 
carbimazole was 98%. The cure rate of the 27 patients on carbimazole treatment given before RAI administration was 81%, and 73% in 
the 37 patients in whom it was resumed after RAI administration. The overall cure rate was lower in patients who received carbimazole 
(p<0.001), but especially in patients in whom carbimazole was continued after RAI administration (p<0.001).
Conclusions. Adjunctive carbimazole treatment decreased the RAI cure rate of Graves’ disease significantly.
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Carbimazole treatment was discontinued 
7 - 10 days before RAI administration. 
Resumption of carbimazole treatment was 
mostly delayed for about 2 - 3 weeks after 
RAI administration, with reliance on beta-
adrenergic blockade in the interim to control 
symptoms of hyperthyroidism if necessary. 
The outcome from 3 months was assessed 
as euthyroid, hypothyroid or residual 
hyperthyroid. This was based on reduced 
serum T4 and increased TSH values. 
Treatment was regarded as successful at 
6 months and sustained at 12 months if 
the patient was biochemically euthyroid or 
hypothyroid. If treatment was deemed to be 
unsuccessful at 3 months, a second dose of 
RAI was administered. 
Permission to conduct the study was 
granted by the Research Ethics Committee 
of the Faculty of Health Sciences of the 
University of Pretoria (ref. no. 337/2016) 
Data analysis
Cure rate at 6 months was calculated as 
a proportion. Observed data were mainly 
nominal/ordinal in nature and were 
summarised using frequency, percentage, 
cross-tables and 95% confidence intervals. 
Factors associated with outcome were 
assessed using odds ratios for univariate 
analysis and adjusted odds ratio from 
multivariate logistic regression analysis. The 
Stata statistical software 12.1 (StataCorp., 
USA) was utilised for statistical analysis 
and a p-value of ≤0.05 was regarded as 
significant. 
Results
One hundred and seventy-one patients 
with Graves’ disease were treated with RAI 
(Table 1). The mean (standard deviation (SD)) 
age was 43.2 (13.1) years (range 8 - 79). There 
was a strong female predominance of 144 of 
171 patients (84%). The majority of males 
(16/27; 60%) were 40 years of age or younger, 
whereas the majority of females (96/144; 
67%) were 40 years of age or older. Patients 
presented with typical symptoms and signs of 
hyperthyroidism. All patients showed a diffuse 
increase uptake on 123I or Tc 99m uptake scan 
(see Fig. 1 for a representative scan).
The mean (SD) therapeutic ablation dose of 
131I was 15.4 (2.3) mCi. This ranged between 
5 and 25 mCi, and was given as a single oral 
dose.
The sex and age of the patients was found to 
have no significant influence on the cure rate 
(p=0.73). The only effect of the patients’ age 
on the cure rate was in patients older than 60 
years, who were more likely to be cured by a 
single dose of RAI (p=0.027).
Patients receiving a higher initial RAI dose 
were more likely to be cured (Table 2). The 
overall cure rate after initial RAI dose was 
90% (153/171). However, when divided 
doses were assessed (low ≤15 mCi and high 
>15 mCi), there was a significant association 
between the RAI dose and the cure rate 
(p=0.05), with more patients cured on the 
higher RAI dose. 
Complete ATD treatment data were 
available for 169 patients. The requirement 
for a second RAI dose correlated with the use 
of carbimazole (Spearman’s rank correlation 
coefficient with Bonferroni adjustment 
r=0.38; p<0.001). Fourteen patients received a 
second dose of RAI, all of whom had received 
carbimazole. Seventy-two patients (43%) 
received carbimazole treatment. The use of 
carbimazole adversely affected the cure rate 
(Table 3). Patients who received carbimazole 
treatment at any time had a lower cure rate 
(81%) than those who did not receive it 
(p<0.05). Patients who received carbimazole 
both before and after RAI administration had 
an even lower cure rate of 73% (27/37). This 
is significantly lower than the overall cure 
rate of 90% (p<0.001). Patients who received 
carbimazole before RAI administration only 
had a cure rate of 96%, which is similar to 
the cure rate in patients who did not receive 
carbimazole (95/97; 98%). TFTs (TSH and 
T4) are shown in Table 4. 
Discussion
In this study, 90% of patients were cured 
of hyperthyroidism by RAI therapy. This 
is similar to recently published studies. 
Sundaresh et al.[9] reported a successful 
outcome in 92% of patients. However, cure 
rates as low as 77% have been reported.[10] 
Patients who received a lower dose of RAI 
had a poorer outcome and consequently 
required a second dose. This corresponds to 
the universal finding of previous studies in 
which higher cure rates are achieved with a 
higher initial dose of RAI.[11-14]
The cure rate in this study was 
significantly influenced by use of 
carbimazole. A poorer outcome was found 
in patients who received carbimazole before 
and/or after RAI administration, but not 
Table 1. Clinical details of patients 
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Fig. 1. A representative thyroid technetium-99m uptake scan for patients with Graves’ disease. 
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in those receiving carbimazole before RAI treatment only. Many 
clinicians prefer to render their patients euthyroid with ATDs 
before RAI in order to stabilise the disease and to minimise the 
risk of exacerbation of hyperthyroidism.[11] Older patients are more 
susceptible to complications of hyperthyroidism and may require 
control with ATDs during RAI treatment.[1] However, ATDs may 
confer a so-called radioprotective effect, making RAI less effective 
and possibly resulting in RAI treatment failure.[12,13]
On the other hand, some clinicians continue ATD treatment after 
administration of RAI. This is done to control ongoing symptoms 
of hyperthyroidism in vulnerable patients, and because there is 
a lag period of 6 - 8 weeks before involution of thyrocytes due to 
radioactivity.[4]
In almost all studies, outcome of RAI is poorer if associated with 
ATD treatment, irrespective of the timing.[12,13] In a meta-analysis of 
randomised trials, Walter et al.[15] reported that there was a risk of 
treatment failure with ATD treatment both before (risk ratio 1.48) 
and after (risk ratio 1.32) RAI administration. The adjunctive use of 
ATDs is, nevertheless, widespread. In our patients the highest cure 
rate (98%) was in the group who did not receive carbimazole. Poorer 
outcome was seen in patients who received carbimazole at any time, 
but especially when it was continued after RAI administration (75% 
cure rate). This is in contrast to the outcome in patients receiving 
carbimazole before RAI administration only (96% cure rate). This 
result is similar to that obtained in a prospective study performed 
by Andrade et al.[14] in which pretreatment with methimazole had 
no effect on the cure rate of Graves’ disease 1 year after treatment 
with RAI.
Only a few studies have investigated the effect of ATD use after 
RAI, and the findings have been mixed. Bonnema et al.[16] found that 
the resumption of methimazole after RAI administration did not 
affect the outcome of RAI. Several older studies found that the use of 
ATDs after RAI reduced the therapeutic effect of RAI.[17-19] 
Limitations of the study include its retrospective nature; there was 
no uniform or standardised treatment and data collection. Patients 
were managed severally and simultaneously by both clinicians 
and nuclear medicine specialists, leading to some differences in 
adjunctive treatment. Furthermore, the requisite data were obtained 
Table 2. Cure rate in Graves’ disease patients who received different radioactive iodine doses
RAI dose, mCi Patients, n Cured, n* Received 2nd RAI dose, n Cure rate, %
<10 28 24 3† 86
10.1 - 15 60 52 6† 87
15.1 - 20 59 55 4 93
>20 24 22 1† 92
Total 171 153 14† 90
RAI = radio-iodine.
*Cured = euthyroid or hypothyroid state.
†Some patients were lost to follow-up.
Table 3. Outcome of RAI treatment in patients with Graves’ disease with or without adjunctive ATD treatment
ATD timing* Cured,† n (%) Persistently hyperthyroid, n (%) p-value (v. no carbimazole)
ATD pre RAI only (n=27) 26 (96) 1 (4) 0.52
ATD pre and post RAI (n=37) 27 (73) 10(27) <0.001
ATD at any time  (n=72)‡ 58 (81) 14 (19) <0.001
ATD post RAI only (n=8) 5 (63) 3 (38)
ATD not used (n=97) 95 (98) 2 (2)
RAI = radio-iodine; ATD = antithyroid drug carbimazole.
*Carbimazole was suspended for 7 - 10 days before administration of RAI dose.
†Cured = hypothyroid or euthyroid at 12 months.
‡Eight patients received carbimazole after RAI only.
Table 4. Thyroid function tests before and after RAI ablation in Graves’ disease patients with or without carbimazole treatment, 
mean (SD)
Pre-ablation 3 months 6 months 9 - 12 months
Total group
TSH (n=147) <0.03 (n=148) 64.5 (28.7) (n=98) 55.3 (34.4) (n=83) 43.8 (31.1)
T4 (n=130) 59.6 (23) (n=123) 38.4 (39.0) (n=94) 26.5 (22.4) (n=77) 11.0 (6.7)
Carbimazole post RAI
TSH (n=33) 0.03 (0.03) (n=29) 67.5 (45.9) (n=24) 45.3 (22.0) (n=18) 56.5 (37.6)
T4 (n=30) 64.0 (25.6) (n=29)59.2 (54.4) (n=24) 35.6 (31.9) (n=17) 16.0 (14.4)
No carbimazole post RAI
TSH (n=101) 0.02 (0.03) (n=91) 65.9 (27.1) (n=72) 57.0 (36.2) (n=60) 41.3 (29.7)
T4 (n=91) 58.3 (23.7) (n=87) 23.3 (18.2) (n=68) 19.4 (7.05) (n=56) 9.8 (2.85)
RAI = radio-iodine; SD = standard deviation; TSH = thyroid-stimulating hormone; T4 = thyroxine.
NB: (i) it is the practice that once patients have been deemed cured (i.e. euthyroid or hypothyroid) they are referred back to their originating hospitals, and therefore no follow-up is done at our 
tertiary hospital; (ii) the TFT data need to be interpreted with caution, since many patients were already placed on thyroxine replacement therapy, based on earlier results showing a hypothyroid 
state. 
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from different treatment sites with different diligence in data storage; 
this means some data should be interpreted with caution.
Conclusions
RAI was found to be a highly effective modality of treatment for 
Graves’ disease but may be affected by the use of carbimazole. 
This study confirms that carbimazole reduces the RAI cure rate of 
Graves’ disease, especially if used after administration of the RAI 
dose. Our study therefore recommends that carbimazole should be 
discontinued after RAI administration if it was used beforehand, 
and if its use is indicated for symptom control after RAI, it should be 
postponed for at least 2 weeks and reliance placed on the use of beta-
adrenergic blockers during this time.
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